Clostridium difficile infection (CDI) has emerged as a significant nosocomial infection over the years with increased incidence, recurrence and need for hospitalization. About 15% to 30% of patients who initially respond to antimicrobial therapy experience recurrent CDI (rCDI). After the first recurrence, the risk ...
Find MoreClostridium difficile Infection (CDI), one of the most common nosocomial and community-acquired infections globally, is a major public health challenge. The Clostridium difficile bacteria are a toxin-producing pathogen that produces two types of toxins: toxin A (an enterotoxin) and toxin B (a cytotoxin). This toxin...
Find MoreThe American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.